Short term efficacy of Upatinib in the treatment of 12 patients with severe alopecia areata
Objective To observe short term efficacy and safety of Upatinib in the treatment of severe alopecia areata.Methods From March 2023 to March 2024,12 patients with severe alo-pecia areata were treated orally with sustained-release tablets of Upatinib at the dermatology outpa-tient clinic of the First Affiliated Hospital of Henan University of Science and Technology.After 12 weeks of the treatment,the clinical efficacy and adverse reactions were evaluated.Results After 12 weeks of the treatment,there were 10 patients(83.33％)with SALT≤20 points.The average hair density was increased from 29.42±3.23/0.46 cm2 at baseline to 35.50±2.87/0.46 cm2(t=27.62,P＜0.001).The average hair diameter was also increased from(39.58±2.35)µm to(67.75±6.43)μm(t=14.26,P＜0.001).No serious adverse reactions were observed in all patients.Conclusions Upatinib is effective and safe for severe alopecia areata,and can be an optional therapeutic approach for severe alopecia areata.
Upatinibalopecia areatasevereobservation on the efficacy
国家科技期刊平台
NSTL
万方数据
